HydroxyBurn Shred Ultra Nootropic Thermogenic Passionfruit

Australia - English - Department of Health (Therapeutic Goods Administration)

Buy It Now

Active ingredient:
acetyl levocarnitine hydrochloride,Bacopa monnieri,caffeine,chromic chloride hexahydrate,Camellia sinensis,Coffea canephora,Garcinia gummi-gutta,inositol,nicotinic acid,Paullinia cupana,Withania somnifera
Available from:
Body Science International Pty Ltd
Authorization status:
Listed
Authorization number:
321828

Public Summary

Summary for ARTG Entry:

321828

HydroxyBurn Shred Ultra Nootropic Thermogenic Passionfruit

ARTG entry for

Medicine Listed

Sponsor

Body Science International Pty Ltd

Postal Address

PO Box 2070,BURLEIGH BC, QLD, 4220

Australia

ARTG Start Date

15/08/2019

Product category

Medicine

Status

Active

Approval area

Listed Medicines

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in

the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine,

(b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is

sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be

kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records

to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted

in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office

of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors

of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified

of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine

outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National

Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1. HydroxyBurn Shred Ultra Nootropic Thermogenic Passionfruit

Product Type

Single Medicine Product

Effective date

15/08/2019

Permitted Indications

Enhance/promote energy levels

Maintain/support calorie burning

Helps improve/promote body metabolism/metabolic rate

Enhance/promote/physical endurance/capacity/stamina

Maintain/support heat/energy production/thermogenesis

Helps enhance/promote/increase body fat loss

Helps enhance/improve/promote/increase physical/exercise performance

Aids/assists the body to cope with environmental stress

Support healthy stress response in the body

Maintain/support mental concentration/focus/clarity

Enhance/improve/promote/increase cognitive performance

Maintain/support cognitive function/mental function

Enhance/improve/promote/increase mental alertness/wakefulness

Maintain/support memory/mental recall

Support healthy emotional/mood balance

Indication Requirements

Label statement: When used in conjunction with a program of reduced intake of dietary calories and increased physical activity.

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

Product presentation must not imply or refer to imply chronic fatigue syndrome.

Public Summary

Page 1 of

Produced at 29.08.2019 at 04:42:24 AEST

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit www.tga.gov.au for contact information

Standard Indications

No Standard Indications included on Record

Specific Indications

Warnings

Contains caffeine [state quantity per dosage unit or per mL or per gram of product] total caffeine [per dosage unit or per mL or per gram]. A cup of instant

coffee contains approximately 80mg of caffeine.

Adults only (or words to that effect).

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1. Formulation 1

Dosage Form

Powder, oral

Route of Administration

Oral

Visual Identification

Active Ingredients

acetyl levocarnitine hydrochloride

400 mg/g

Bacopa monnieri

25 mg/g

Equivalent: Bacopa monnieri (Dry)

500 mg/g

caffeine

10 mg/g

Camellia sinensis

20 mg/g

Equivalent: Camellia sinensis (Dry)

500 mg/g

chromic chloride hexahydrate

40 microgram/g

Coffea canephora

10.4 mg/g

Equivalent: Coffea canephora (Dry)

520 mg/g

Garcinia gummi-gutta

50 mg/g

Equivalent: Garcinia gummi-gutta (Dry)

500 mg/g

inositol

60 mg/g

nicotinic acid

4 mg/g

Paullinia cupana

45 mg/g

Equivalent: Paullinia cupana (Dry)

900 mg/g

Withania somnifera

5 mg/g

Equivalent: Withania somnifera (Dry)

100 mg/g

© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior

written approval from the Commonwealth.Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.

Public Summary

Page 2 of

Produced at 29.08.2019 at 04:42:24 AEST

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit www.tga.gov.au for contact information

Similar products

Search alerts related to this product

Share this information